Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0M4PH
|
||||
| Former ID |
DIB009174
|
||||
| Drug Name |
LOXO-101
|
||||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Approved | [1] | ||
| Company |
Array biopharma; loxo oncology
|
||||
| Target and Pathway | |||||
| Target(s) | BDNF/NT-3 growth factors receptor (TrkB) | Target Info | Inhibitor | [2] | |
| NT-3 growth factor receptor (TrkC) | Target Info | Inhibitor | [3] | ||
| Tropomyosin-related kinase A (TrkA) | Target Info | Inhibitor | [1], [4] | ||
| KEGG Pathway | MAPK signaling pathway | ||||
| Neurotrophin signaling pathway | |||||
| Alcoholism | |||||
| Neurotrophin signaling pathway | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| Pathways in cancer | |||||
| Transcriptional misregulation in cancer | |||||
| Thyroid cancer | |||||
| Central carbon metabolism in cancer | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| Pathway Interaction Database | SHP2 signaling | ||||
| Posttranslational regulation of adherens junction stability and dissassembly | |||||
| Neurotrophic factor-mediated Trk receptor signaling | |||||
| Reactome | NGF-independant TRKA activation | ||||
| NGF-independant TRKA activation | |||||
| PI3K/AKT activation | |||||
| PI3K/AKT activation | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| BDNF signaling pathway | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| NGF signalling via TRKA from the plasma membrane | |||||
| References | |||||
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | ||||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1818). | ||||
| REF 3 | ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol. 2014 Jul;12(7):429-39. | ||||
| REF 4 | Clinical pipeline report, company report or official report of Loxo Oncology. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Wang and Dr. Li.